发明名称 |
Injectable flowable composition comprising buprenorphine |
摘要 |
The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis. |
申请公布号 |
AU2011263478(A1) |
申请公布日期 |
2013.01.10 |
申请号 |
AU20110263478 |
申请日期 |
2011.06.06 |
申请人 |
RB PHARMACEUTICALS LIMITED |
发明人 |
NORTON, RICHARD L.;WATKINS, ANDREW;ZHOU, MINGXING |
分类号 |
A61K9/00;A61K31/485;A61K47/22;A61K47/34 |
主分类号 |
A61K9/00 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|